Alkaloid opened new horizons in the treatment of GERB with liquid omeprazole: in Zagreb the first International Conference on Innovative Solutions in the treatment of GERB

As the holder of the first international value -added drug patent – omeprazole in liquid form: ready for use – « Alc

Aloid ”was the patron of the first international conference on a modern approach to the treatment of GERB in pediatric patients, organized in Zagreb, Croatia.

More than 200 health professionals in the field of pediatrics, gastroenterhepathology, nutritionism, pharmacy and pharmacology experts, representatives of the academic community, as well as representatives of Alkaloid participated in the first global event under the auspices of the company dedicated to the latest. the young children. The event was focused on the first patented liquid omeprazole, an innovation that brings significant improvements to the pediatric treatment of this often disease.

Omeprazole belongs to the group of proton pump inhibitors and is a first -choice therapy in the treatment of GERB, traditionally available in the form of gastric tablets, capsules or dissolution powder, which makes it difficult to apply to infants older than one month, young children, patients with patients, and patients with patients,
geriatric patients. Alkaloid for the first time in history has managed to develop omeprazole in patented liquid form, providing a new, practical and effective approach to the treatment of these sensitive patients.

– This product emphasizes the dedication of Alkaloid to top achievements in the field of pharmacy and sets new standards in the generic drug production, with a focus on innovation and market differentiation. The Alkaloid -added innovative drug is already opening new horizons in the treatment of GERB in pediatric patients, primarily in terms of the availability of therapy, which was not the case before, showing positive results in the treatment of these.
Sensitive groups of patients and improving the quality of life of the families facing this often disease – said Zivko Mukaetov, CEO and President of the Alkaloid Board.

After patenting in September 2023, liquid omeprazole was first launched in February 2024 in markets in Macedonia and the United Kingdom, and this international conference was an excellent opportunity to exchange clinical experiences, as well as to share good practices and innovative approaches in pediatric practice. Health professionals from
Macedonia, the United Kingdom, Belgium, from Slovenia, Croatia, BiH, Bulgaria, Romania, Serbia and Kosovo discussed the challenges they face in the treatment of GERB, as well as the benefits of introducing this innovative formulation of omeprazole, pointing to its efficacy and its safety.

A team of experts from various fields in Alkaloid has been working on the development of liquid omeprazole for 6 years.

The innovative concept of this medicine includes a two -time disposable bottle, which contains two solutions separately – one with high pH and one diluent. Mixing the solutions shortly before use gives a stable formulation with optimal pH value, which protects the active substance from degradation when contact with gastric acid, enabling appropriate, safe and effective application of pediatric patients as well as other sensitive groups. To meet the specific requirements in the process of producing this medicine, Alkaloid invested in a dedicated machine, suitable for this innovative product, ensuring efficient and sustainable
Chain of his delivery around the world.

Omeprazole The solution is available in markets in Macedonia, Britain, Ireland, Romania and Croatia. Currently, the product is in the process of obtaining marketing authorization in many other countries.